Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02FXK
|
|||
| Former ID |
DAP001272
|
|||
| Drug Name |
Botulinum Toxin Type B
|
|||
| Synonyms |
BTXA (TN); Dysport (TN); Myobloc (TN); Neurobloc (TN); Xeomin (TN)
Click to Show/Hide
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-9: 332] | Approved | [1] | |
| Therapeutic Class |
Antidystonic Agents
|
|||
| Company |
Allergan Inc
|
|||
| ADReCS Drug ID | BADD_D01943 | |||
| SuperDrug ATC ID |
M03AX01
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vesicle-associated membrane protein (VAMP) | Target Info | Binder | [2], [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 2 | Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling. J Neurol. 2009 Apr;256(4):563-7. | |||
| REF 3 | Botulinum toxin type A and type B for sialorrhoea in Parkinson's disease: a case for switching therapy J Rehabil Med. 2008 Nov;40(10):882-3. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.